RXRX241227P9500
- 0.00
- 0.000.00%
Recursion Pharmaceuticals Newsroom
Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment
Trending Industry Today: Arm Holdings Leads Losses In NVIDIA Portfolio Stocks
Is Recursion Pharmaceuticals Stock a Millionaire Maker?
Express News | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
Trending Industry Today: Applied Digital Leads Gains Pre-Market In NVIDIA Portfolio Stocks
Trending Industry Today: Serve Robotics Leads Losses In NVIDIA Portfolio Stocks
Express News | Recursion Pharmaceuticals Inc - Registering for Resale 3.5 Mln Shares of Class a Common Stock
Express News | Recursion Pharmaceuticals Inc - Files Prospectus Supplement
Trending Industry Today: SoundHound AI Leads Losses In NVIDIA Portfolio Stocks
Jim Cramer Says He Was Wrong on NVIDIA Holding Recursion Pharmaceuticals (RXRX)
Trending Industry Today: SoundHound AI Leads Gains In NVIDIA Portfolio Stocks
Trending Industry Today: Applied Digital Leads Gains In NVIDIA Portfolio Stocks
Recursion Pharmaceuticals' (RXRX) AI-Driven Cancer Treatment Shows Promise in Early Trials
Hold Rating for Recursion Pharmaceuticals Amid Early Efficacy Signals and Financial Concerns
10 Health Care Stocks Whale Activity In Today's Session
Why Recursion Pharmaceuticals (RXRX) Is the Worst ARK Stock to Buy According to Short Sellers
Needham Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Maintains Target Price $11
Express News | Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $11 Price Target
Recursion Pharmaceuticals Analyst Ratings
TD Cowen Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating